Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Anavex Life Sciences Corp. (12X1.F)

Compare
7.91
+0.21
+(2.70%)
At close: April 15 at 9:00:34 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Christopher U. Missling M.B.A., M.S., Ph.D. President, CEO, Secretary & Director 755.02k -- 1966
Ms. Sandra Boenisch CPA, CGA Principal Financial Officer & Treasurer 184.79k -- 1981
Dr. Walter E. Kaufmann M.D. Chief Scientific Officer -- -- --
Clint Tomlinson VP of Corporate -- -- --
Dr. Adebayo Laniyonu Ph.D. Senior Vice President of Nonclinical Development -- -- --
Dr. Edward R Hammond M.D., M.P.H., Ph.D. Chief Medical Officer -- -- --
Dr. Kun Jin Ph.D. Head of Biostatistics -- -- --
Mr. David Goldberger R.Ph. Senior Vice President of Regulatory Affairs -- -- --
Dr. Terrie Kellmeyer Ph.D. Senior Vice President of Clinical Development -- -- --
Dr. Juan Carlos Lopez-Talavera M.D., Ph.D. Senior VP & Head of Research and Development -- -- --

Anavex Life Sciences Corp.

630 5th Avenue
20th Floor
New York, NY 10111
United States
844 689 3939 https://www.anavex.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
42

Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2001 and is headquartered in New York, New York.

Corporate Governance

Anavex Life Sciences Corp.’s ISS Governance QualityScore as of April 1, 2025 is 4. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 1; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC

Anavex Life Sciences Corp. Earnings Date

Recent Events

Related Tickers